Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

Impact · against what's priced in

Endovia (EDVA) has achieved a key regulatory milestone by qualifying CannEpil for the FDA's conditional approval pathway for canine bone cancer pain. This significantly reduces the data burden for initial market entry and sets a clear trajectory for a potential 2027 commercial launch.

EDVA+0.60

No priced-in read yet